Last edition
News about " BriaCell"
BriaPro to Acquire Worldwide Rights to Soluble CD80 Immunotherapy from BriaCell
BriaCell Therapeutics Corporation and its majority-owned subsidiary BriaPro Therapeutics Corporation have entered into a definitive purchase agreement under which BriaPro will acquire BriaCell’s exclusive license to develop and commercialize Soluble CD80 (sCD80) as a biologic therapy for cancer, along with related assets.
BriaCell | 22/02/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members